Muscle-invasive bladder cancer patients who are ineligible or refuse cisplatin chemotherapy see “dramatic” improvements in survival outcomes with enfortumab vedotin plus pembrolizumab.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ev-pembro-beats-soc-cisplatin-ineligible-bladder-cancer-2025a1000sgy?src=rss
Author :
Publish date : 2025-10-20 19:09:00
Copyright for syndicated content belongs to the linked Source.
